Koo Kwang-mo visited Toronto, Canada, to look at market trends in future business areas in bio and artificial intelligence (AI).
김지선
stockmk2020@alphabiz.co.kr | 2023-08-25 03:18:51
[Alpha Biz=(Chicago) Reporter Kim Jisun] According to LG on the 24th, Chairman Koo visited LG Chem Life Science Headquarters' Boston subsidiary (Innovation Center), US pharmaceutical company AVEO, which LG Chem acquired this year, and LG Electronics' Toronto AI Lab (Lab) for four days from the 21st (local time).
Chairman Koo first met with LG Chem Life Sciences head Sohn Ji-woong, Boston branch head Lee Dong-soo and CEO Michael Bailey Abeo at the Boston Innovation Center to examine the direction of the new drug business and ways to strengthen global commercialization capabilities and discuss strategies to foster them.
Koo examined strategies for developing innovative new drugs such as anti-cancer drugs and cell therapy drugs, and also looked at the status of strengthening business competitiveness after the acquisition of Abeo.
LG Chem's Life Sciences Division is speeding up its entry into the U.S. market, which accounts for more than half of the global innovative new drug market. The goal is to become a global top-tier pharmaceutical company by 2030.
[ⓒ AlphaBIZ. 무단전재-재배포 금지]
많이 본 기사
- 1Samsung Electronics Labor Talks Collapse Again as Union Rejects “Industry-Leading” Compensation Proposal
- 2Korea Exchange Flags 76 Suspected Short-Selling Violations via Monitoring System
- 3NH Investment & Securities Cuts NAVER Target Price to KRW 320,000, Maintains ‘Buy’ on AI Growth Outlook
- 4Naver Revises Dormant Account Policy for Mail Service to Cut Costs and Reduce Spam Traffic
- 5Lotte Group to Launch KRW 50 Trillion Real Estate Development Push to Tackle Liquidity Pressures
- 6Amazon Web Services to Invest KRW 7 Trillion More in Korea by 2031, Expanding AI Infrastructure